VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/ ...

The company’s financial position was further strengthened by a $150 million upfront payment from a licensing agreement with Novartis for VAV1 molecular glue degraders. Additionally, Monte Rosa ...

BOSTON—Leo Chandra P., a director at Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE), recently made a significant purchase of the company’s stock.According to a recent SEC filing, Chandra ...

Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in ...

Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical ...

Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical ...

In the case of MRT-6160, it is specifically designed to modulate the VAV1 protein expression. What's so special about this protein? This specific protein modulates downstream activity of T-cell ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is ...

MRT-6160 is a potent, highly selective, and orally bioavailable investigational degrader of VAV1, a key signaling protein downstream of both the T- and B-cell receptors. Preclinical studies have ...